MediWound initiates the VALUE Global Phase III trial of EscharEx

MediWound (MDWD) announced the initiation of VALUE, a global, pivotal Phase III trial evaluating EscharEx for the treatment of venous leg ulcers. “We are proud to initiate the VALUE study, the most comprehensive VLU trial in over a decade,” said Ofer Gonen, Chief Executive Officer of MediWound. “With no new FDA-approved drugs in this category since 1965, EscharEx has the potential to redefine the standard of care for chronic wound debridement. EscharEx has already demonstrated its ability to effectively and rapidly debride chronic wounds in multiple Phase II trials, surpassing the current $375+ million market leader in wound debridement, SANTYL. We are confident that EscharEx will provide meaningful benefits to patients, healthcare providers, and payors alike.”